Clovis stock gets a boost from Citadel investment
BOULDER — Clovis Oncology Inc.’s (Nasdaq: CLVS) stock price, which has taken a beating in the last year, jumped about 10 percent in early trading Friday following a disclosure that Citadel Advisors LLC had bought roughly 3.6 million shares. The stock price finished trading Friday at $5.60, up 7.69 percent.
Citadel’s investment represents 7 percent of Clovis’ shares, according to documents filed with the U.S. Securities and Exchange Commission.
Citadel is a Chicago-based investment firm led by CEO Kenneth Griffin.
SPONSORED CONTENT
Business Cares: March 2024
WomenGive, a program of United Way of Larimer County, was started in Larimer County in 2006 as an opportunity for women in our community to come together to help other women.
Despite the positive momentum, Clovis’ stock price is still down significantly from its 52-week high of $37.27. The stock has lost roughly 80 percent of its value in the last six months.
Earlier this month, the company announced $225 million in a private offering. That offering followed a report that Clovis posted a loss-per-share of $2.27 for Q2 2019, far greater than analyst estimates of a loss of $1.71 per share.
BOULDER — Clovis Oncology Inc.’s (Nasdaq: CLVS) stock price, which has taken a beating in the last year, jumped about 10 percent in early trading Friday following a disclosure that Citadel Advisors LLC had bought roughly 3.6 million shares. The stock price finished trading Friday at $5.60, up 7.69 percent.
Citadel’s investment represents 7 percent of Clovis’ shares, according to documents filed with the U.S. Securities and Exchange Commission.
Citadel is a Chicago-based investment firm led by CEO Kenneth Griffin.
Despite the positive momentum, Clovis’ stock price is still down significantly from its…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!